tetano
Editor, Senior Moderator
Transpl Infect Dis. 2020 May 14:e13326. doi: 10.1111/tid.13326. [Epub ahead of print]
Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.
Allam SR[SUP]1,[/SUP][SUP]2[/SUP], Dao A[SUP]2[/SUP], Madhrira MM[SUP]1,[/SUP][SUP]2[/SUP], Antiporta PB[SUP]3[/SUP], Nair RR[SUP]4[/SUP], Guiteau JJ[SUP]2[/SUP], Reyad AI[SUP]2[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS-CoV-2 induced inflammatory syndrome by utilization of the interleukin-6 receptor antagonist (IL-6Ra) tocilizumab.
This article is protected by copyright. All rights reserved.
PMID:32406985DOI:10.1111/tid.13326
Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.
Allam SR[SUP]1,[/SUP][SUP]2[/SUP], Dao A[SUP]2[/SUP], Madhrira MM[SUP]1,[/SUP][SUP]2[/SUP], Antiporta PB[SUP]3[/SUP], Nair RR[SUP]4[/SUP], Guiteau JJ[SUP]2[/SUP], Reyad AI[SUP]2[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS-CoV-2 induced inflammatory syndrome by utilization of the interleukin-6 receptor antagonist (IL-6Ra) tocilizumab.
This article is protected by copyright. All rights reserved.
PMID:32406985DOI:10.1111/tid.13326